Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01921023
Other study ID # PROX006
Secondary ID
Status Completed
Phase N/A
First received August 8, 2013
Last updated November 17, 2014
Start date September 2014
Est. completion date October 2014

Study information

Verified date February 2014
Source Sphere Medical Ltd.
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Observational

Clinical Trial Summary

This clinical investigation is being undertaken to examine the performance of the CE marked Proxima System - a patient attached blood gas analyser.

The study forms an element of the Post Market surveillance plan for the Proxima system and will also generate method comparison data to allow Sphere Medical to submit the Proxima for FDA regulatory clearance.


Description:

The PROX006 study is an open and non-randomised study that will be conducted to assess the performance of the Proxima (a CE marked Medical Device)on a wide range of patients with a variety of conditions. This study will allow the performance of the Proxima and the institution's conventional blood gas analyser to be compared when used in the Intensive Care Unit and Operating Theatre.

The PROX006 investigation is an observational method comparison study - the results obtained from the Proxima will be compared with those obtained on the institution's conventional blood gas analyser (BGA). The potential for bias by the user will be negated in this study by directly comparing the results from the BGA and Proxima.

The data/results documented in the Case Report Form (CRF) will be verified during monitoring visits.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male and female patients =18 years old

- Patients who have (or will have) an arterial line, which was (will be) inserted for clinical need, will be considered for inclusion in this study

- Patients who give informed consent (or their personal/nominated consultee) to participate in the study

- Patients who are likely to have an arterial line for at least 48 hours.

Exclusion Criteria:

- Patients not indicated or contraindicated for an arterial line

- Refusal of consent by a patient or their personal/nominated consultee to participate

- Not for use with patients with uncorrected hyperphosphataemia, hypocalcaemia or hypercalcaemia.

- The patient is considered by the investigator to be unsuitable for the study

Arterial line location/placement is not dictated by this study, however the following criteria should be considered when deciding if arterial catheter placement is suitable, including but not limited to:

- peripheral vascular disease,

- history of placement site neuropathy or chronic pain,

- history of placement extremity coagulopathy or clot formation,

- history of vascular surgery on same extremity as catheter placement (and/or vascular grafts)

- patients with a plan for perioperative anticoagulation. These patients are at increased risk of known complications such as bleeding and arteriospasm and should be excluded in order to mitigate patient study risk.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Queen Elizabeth Hospital City and Borough of Birmingham Edgbaston

Sponsors (1)

Lead Sponsor Collaborator
Sphere Medical Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary - To obtain quantitative data using patient arterial blood to allow the comparison of Proxima readings with those obtained from a standard commercially available blood gas analyser in a clinical setting. Blood gas samples will be analysed on the Proxima and institution's Blood Gas Analyser.
Additional samples for serum phosphate analysis will be draw and analysed every 24 hours for 3 days.
1 day follow up period after the Proxima system has been disconnected from the patient
4 days for each patient Yes
See also
  Status Clinical Trial Phase
Completed NCT03242525 - Examination of the Time Advantage Between POCT and Conventional Central Laboratory Analysis
Completed NCT01423942 - Maturation of the Autonomic Nervous System in Prematures N/A
Completed NCT02919657 - Absorption Comparison on Equivalency Value of Genepro Gen2 Phase 4
Completed NCT02838654 - Cervical Epidural Waveform Analysis Using Pressure Monitoring Kit N/A
Completed NCT03245294 - Factors Contributing to the Pressure Wave Form Changes N/A